Fusen Pharmaceutical Co (HKSE:01652) ROCE % : -13.70% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Fusen Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fusen Pharmaceutical Co's annualized ROCE % for the quarter that ended in Dec. 2023 was -13.70%.

Fusen Pharmaceutical Co ROCE % Historical Data

The historical data trend for Fusen Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusen Pharmaceutical Co ROCE % Chart

Fusen Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

10.12

12.87

4.51

-2.57

-2.55

Fusen Pharmaceutical Co Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial											-6.42	-0.29	-5.02	8.83	-13.70

Fusen Pharmaceutical Co ROCE % Calculation

Fusen Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-18.447	/	( ( (1507.864 - 806.36)	+	(1469.76 - 726.838) )	/ 2 )
	=	-18.447	/	( (701.504	+	742.922)	/ 2 )
	=	-18.447	/	722.213
	=	-2.55 %

Fusen Pharmaceutical Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-98.55	/	( ( (1435.479 - 739.858)	+	(1469.76 - 726.838) )	/ 2 )
	=	-98.55	/	( ( 695.621	+	742.922 )	/ 2 )
	=	-98.55	/	719.2715
	=	-13.70 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Fusen Pharmaceutical Co (HKSE:01652) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Fusen Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Fusen Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusen Pharmaceutical Co (HKSE:01652) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fusen Pharmaceutical Co Ltd (HKSE:01652) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Urban Industrial Zone, Henan Province, Xichuan County, Zhengzhou, CHN

Website

http://www.fusenyy.com

Fusen Pharmaceutical Co Ltd is engaged in manufacturing shuanghuanglian based cold medicine. The product portfolio company includes shuanghuanglian based cold medicine and which includes oral solutions and shuanghuanglian injections, other PCM and western medicine products which include compound ferrous sulphate granules and flunarizine hydrochloride capsules.

Executives

Cao Changcheng	2201 Interest of corporation controlled by you
Quan Xiufeng	2202 Interest of your spouse
Full Bliss Holdings Limited	2101 Beneficial owner
One Victory Investments Limited	2101 Beneficial owner
Cao Zhiming	2201 Interest of corporation controlled by you
Zhou Peilin	2202 Interest of your spouse
Rayford Global Limited	2306 Nominee for another person
Tct (bvi) Limited	2501 Other
The Core Trust Company Limited	2301 Trustee
First Joint Elegant Limited	2101 Beneficial owner
Fung Wai Sze	2202 Interest of your spouse
Lam Yiu Por	2201 Interest of corporation controlled by you

Fusen Pharmaceutical Co (HKSE:01652) Headlines

No Headlines